Nirvana Life SciencesNIRVF EV-to-FCF is -1.40 as of Jul. 03, 2026. The stock has 3 warning signs investors should review. Among 332 Biotechnology companies, Nirvana Life Sciences ranks worse than 301204.52% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nirvana Life Sciences's Enterprise Value is $0.90 Mil.
Nirvana Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2026 was $-0.64 Mil. Therefore, Nirvana Life Sciences's EV-to-FCF for today is -1.40.
The historical rank and industry rank for Nirvana Life Sciences's EV-to-FCF or its related term are showing as below:
NIRVF'
s EV-to-FCF Range Over the Past 10 Years
Min: -1.45 Med: 0 Max: 0
Current: -1.45
NIRVF's EV-to-FCF is ranked worse than 100% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs NIRVF: -1.45
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nirvana Life Sciences (OTCPK:NIRVF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nirvana Life Sciences's PE Ratio (TTM) for today is calculated as:
Nirvana Life Sciences's share price for today is $0.08.
Nirvana Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.007.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nirvana Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nirvana Life Sciences EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nirvana Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nirvana Life Sciences's EV-to-FCF falls into.
Nirvana Life Sciences's current Enterprise Value is $0.90 Mil.
Nirvana Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nirvana Life Sciences (NIRVF) has a EV-to-FCF of -1.40 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nirvana Life Sciences and its competitors. According to the industry distribution chart, Nirvana Life Sciences ranks #999999 out of 332 companies in the Biotechnology industry.
Is Nirvana Life Sciences' EV-to-FCF too high?
Nirvana Life Sciences' current EV-to-FCF is -1.40. Based on the distribution chart, Nirvana Life Sciences ranks #999999 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nirvana Life Sciences' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nirvana Life Sciences ranks #999999 out of 332 companies for EV-to-FCF. This places Nirvana Life Sciences in the lower half of its industry. The industry median EV-to-FCF is 16.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nirvana Life Sciences and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nirvana Life Sciences's current EV-to-FCF is -1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nirvana Life Sciences stock overvalued right now?
Nirvana Life Sciences (NIRVF) has a current EV-to-FCF of -1.40. The current EV-to-FCF is -1.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Nirvana Life Sciences (NIRVF), the current EV-to-FCF is -1.40 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nirvana Life Sciences Inc is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NIRVF has been successfully added to your 